Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 10 of 40 matches

Category 6 - PATHOLOGY SERVICES

Category 3 - THERAPEUTIC PROCEDURES

Cytotoxic Chemotherapy Administration - (Item 13950)

Category 3 - THERAPEUTIC PROCEDURES

Appropriate billing of item 13950 – parenteral administration of antineoplastic agents

Category 3 - THERAPEUTIC PROCEDURES

Referred Anaesthesia Consultations - (Items 17640 to 17655)

Category 3 - THERAPEUTIC PROCEDURES

Urology Oncology: Bladder Excision or Transection - (Items 37000 and 37014)

Category 3 - THERAPEUTIC PROCEDURES

Peritonectomy surgery - (item 30732)

Category 3 - THERAPEUTIC PROCEDURES

13760

13760 - Additional Information

Item Start Date:
01-Jul-1996
Description Updated:
01-Mar-2026
Schedule Fee Updated:
01-Jul-2026

Group
T1 - Miscellaneous Therapeutic Procedures
Subgroup
8 - Haematology

In vitro processing with cryopreservation of bone marrow or peripheral blood, for autologous stem cell transplantation for a patient receiving high‑dose chemotherapy for management of:

(a) aggressive malignancy; or

(b) malignancy that has proven refractory to prior treatment

(H)



Fee: $912.80 Benefit: 75% = $684.60

(See para TN.1.26 of explanatory notes to this Category)

Category 3 - THERAPEUTIC PROCEDURES

13950

13950 - Additional Information

Item Start Date:
01-Nov-2020
Description Updated:
01-Nov-2020
Schedule Fee Updated:
01-Jul-2026

Group
T1 - Miscellaneous Therapeutic Procedures
Subgroup
11 - Chemotherapeutic Procedures

Parenteral administration of one or more antineoplastic agents, including agents used in cytotoxic chemotherapy or monoclonal antibody therapy but not agents used in anti-resorptive bone therapy or hormonal therapy, by or on behalf of a specialist or consultant physician—attendance for one or more episodes of administration

Note: The fee for item 13950 contains a component which covers the accessing of a long-term drug delivery device. TN.1.27 refers



Fee: $129.30 Benefit: 75% = $97.00 85% = $109.95

(See para TN.1.12, TN.1.27 of explanatory notes to this Category)

Category 3 - THERAPEUTIC PROCEDURES

16050

16050 - Additional Information

Item Start Date:
01-Jul-2025
Description Updated:
01-Jul-2025
Schedule Fee Updated:
01-Jul-2026

Group
T3 - Therapeutic Nuclear Medicine
Subgroup
2 - Theranostics

Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer who is:

(a) PSMA-positive as determined by PSMA PET (defined as SUVmax >15 at a single site of disease and SUVmax >10 at all sites of measurable disease) after disease progression and

(b) prior treatment includes at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.

Applicable once per cycle, up to a maximum of 2 cycles in the initial treatment phase.



Fee: $8,208.00 Benefit: 75% = $6,156.00 85% = $8,103.50

(See para TR.3.1 of explanatory notes to this Category)

Category 3 - THERAPEUTIC PROCEDURES

30732

30732 - Additional Information

Item Start Date:
01-Jul-2021
Description Updated:
01-Jul-2021
Schedule Fee Updated:
01-Jul-2026

Group
T8 - Surgical Operations
Subgroup
1 - General

Peritonectomy, lasting more than 5 hours, including hyperthermic intra-peritoneal chemotherapy

Multiple Operation Rule


(Anaes.) (Assist.)

Fee: $4,757.75 Benefit: 75% = $3,568.35

(See para TN.8.205 of explanatory notes to this Category)

Results 1 to 10 of 40 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change